Hospira Australia Pty Ltd
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- Australia
- Registered address
- 1-39 Lexia Pl, Mulgrave, Victoria 3170, Australia (AUS)
- Operations here
- analysislabelmanufacturepack
- FDA identifiers
- FEI 3001174929 · DUNS 758967652
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- VAIDrug Quality Assurance2022-09-02
- NAIDrug Quality Assurance2019-07-02
- NAIDrug Quality Assurance2015-09-15
- OAIDrug Quality Assurance2014-03-04
- VAIDrug Quality Assurance2011-03-21
- NAIDrug Quality Assurance2009-08-25
Drugs this plant is listed as making
8 distinct drugs across 20 products name this site in their FDA label.
- AztreonamHospira, Inc.
- Carboplatinin shortageHospira, Inc.
- DaptomycinHospira, Inc.
- Docetaxel AnhydrousHospira, Inc.
- Methotrexatein shortageHospira, Inc.
- Pamidronate DisodiumHospira, Inc.
- TopotecanHospira, Inc.
- Vincristine SulfateHospira, Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.